Withings buys Biosency to push into respiratory remote monitoring

Withings has acquired Biosency, a Rennes-based startup that makes remote monitoring tools for patients with respiratory conditions. The deal brings certified COPD detection technology under the Withings umbrella and signals the company's push beyond its well-known consumer health devices into serious clinical territory.

Biosency was founded in 2017 and has spent nearly a decade building a modular remote monitoring platform specifically for patients with respiratory insufficiency. Its standout asset is a medically certified algorithm that can detect COPD exacerbations early, before they escalate into medical emergencies. The company already has an established footprint in the French healthcare system.

The Biosency team stays in Rennes and keeps developing the product. Withings says the solution's certification and patient support will continue without interruption.

What's the news?

Withings has acquired Biosency for an undisclosed sum. Key details include:

• Biosency's remote monitoring platform is certified for use with respiratory insufficiency patients
• Its core algorithm detects COPD exacerbations at an early stage
• The Biosency team joins Withings but remains based in Rennes
• Withings says it will handle commercialization and scaling, while Biosency focuses on developing the technology

Withings president Eric Carreel said he sees a direct connection between detecting respiratory exacerbations and the company's existing work on cardiometabolic disease monitoring. Biosency CEO Marie Pirotais said joining Withings would let the team accelerate deployment while keeping the mission intact.

Why does it matter?

COPD is one of the most common chronic diseases in the world and a major driver of hospital admissions. Catching an exacerbation early, before a patient ends up in the emergency room, is a genuine clinical and economic win. That's exactly what Biosency's algorithm is designed to do.

For Withings, this acquisition is a clear step away from the consumer health market it built its name on and toward the kind of clinical, reimbursable remote monitoring that health systems actually pay for. The company already tracks more than 90 biomarkers across its device range. Adding respiratory monitoring gives it a new disease category to work in.

There's also a strategic angle worth noting. Carreel has talked openly about building a strong, independent European player in connected health. Picking up a French startup with certified technology and existing hospital relationships fits that plan.

The context

Withings started as a consumer gadget company. Its first connected scale launched in 2009, and it spent years selling smart scales, blood pressure monitors, and hybrid smartwatches to health-conscious consumers. Over the past few years, though, it has been making a clear shift toward clinical applications and remote patient monitoring.

The broader industry is moving the same way. Remote patient monitoring has gained real traction since the pandemic, with health systems increasingly willing to fund technology that keeps chronic disease patients out of hospital. COPD is a natural target because:

• It affects hundreds of millions of people worldwide
• Exacerbations are a leading cause of unplanned hospitalization
• Early detection directly reduces those admissions
• Remote monitoring fits well into existing respiratory care pathways

Biosency had built clinical credibility but needed scale to grow commercially. Withings has the manufacturing, distribution, and brand recognition to provide that. It's a straightforward match between a company that has validated technology and one that knows how to bring health products to market at volume.

For more information, visit withings.com.